Phase 1 study of chidamide in combination with venetoclax, azacitidine, aclarubicin, cytarabine and G-CSF for refractory/relapsed acute myeloid leukemia: clinical safety, efficacy, and correlative analysis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/41459484/
https://www.chictr.org.cn/, identifier, ChiCTR2200065634.
This phase 1 trial in relapsed/refractory AML showed CACAG plus venetoclax achieved 76.5% overall response and 73.5% complete response rates, with manageable myelosuppression and promising survival, supported by mechanistic single-cell transcriptomic findings.
Acute leukemia during pregnancy: a single center experience with 23 cases, 2012-2022 and literature review - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/41706499/
Our findings suggest that for non-M3 AL patients can sometimes be managed during pregnancy. For M3 patients, early treatment potentially yield favorable outcomes for both the mother and fetus, using...
Single-center study of 23 pregnancy-associated acute leukemia cases showed 77% response, comparable to general population. Short treatment delay did not worsen prognosis. Non-M3 cases may defer therapy; M3 benefits from early ATRA-based treatment.
Adverse karyotype amplifies risk in secondary acute myeloid leukemia (AML) and AML with myelodysplasia-related changes - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/41666291/
sAML/AML-MRC with an adverse karyotype had a dismal outcome. These findings provide a benchmark for risk stratification in the pre- CPX-351 era.
In a Japanese cohort, secondary AML/AML-MRC showed similar survival to de novo AML after matching. However, adverse karyotype and TP53 mutations significantly worsened outcomes, highlighting cytogenetics as key prognostic determinants.
Reawakening Differentiation Therapy in Acute Myeloid Leukemia: A Comprehensive Review of ATRA-Based Combination Strategies - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/41590345/
(1) Background: All-trans retinoic acid (ATRA) has transformed the treatment of acute promyelocytic leukemia (APL) by inducing terminal myeloid differentiation. However, its efficacy in non-APL acute myeloid leukemia (AML) is...
Comprehensive review examines ATRA-based combination strategies to extend differentiation therapy beyond APL, highlighting synergistic partners, underlying mechanisms, and translational potential for non-APL acute myeloid leukemia.
Emerging Applications of Triazole Antifungal Drugs - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/41596465/
Patients with leukemia are at heightened risk for invasive fungal infections (IFIs) due to profound immunosuppression caused by both the malignancy and its treatment. Chemotherapy-induced neutropenia, mucosal barrier disruption, and...
Review examines triazole antifungals in leukemia, detailing IFI risk, prophylaxis strategies, clinical roles of posaconazole, isavuconazole, voriconazole, and emerging agents, emphasizing individualized, stewardship-driven antifungal management.